Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen - unknown - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - porcine circovirus type 2 orf2 protein; carbomer - misc. vaccines or anti sera - porcine circovirus type 2 orf2 protein vaccine-viral active 1.0 ml/do; carbomer ungrouped other 1.0 mg - immunotherapy - pigs - see label for type - disease control

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - porcine circovirus vaccine (inactivated, recombinant) - immunologicals for suidae, inactivated viral vaccines - pigs (for fattening) - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.,

European Union - English - EMA (European Medicines Agency)

intervet international b.v. - porcine circovirus type 2 (pcv2) orf2 subunit antigen, mycoplasma hyopneumoniae j strain inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs (for fattening) - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (pcv2) infection, and severity of lung lesions caused by mycoplasma hyopneumoniae infection. to reduce the loss of daily weight gain during the finishing period in face of infections with mycoplasma hyopneumoniae and/or pcv2 (as observed in field studies)

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs with no pcv2 maternally derived antibodies from the age of 2 weeks against porcine circovirus type 2 (pcv2),

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines inc.; distributor: zoetis philippines inc. - porcine circovirus (pcv) chimera vaccine (vet.) - suspension for injection (im) - formulation: each 2 ml (dose) contains: inactivated porcine circovirus (pcv) (type 1-2 chimera)............... 21.3 rp rp-relative potency

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines inc.; distributor: zoetis philippines inc. - porcine circovirus (pcv) inactivated chimera vaccine (vet.) - suspension for injection (im) - formulation: each 2 ml (dose) contains: inactivated porcine circovirus (pcv) (type 1-2 chimera)........... ≥ 1.3 rp (type 1-2b chimera)...............≥ 1.3 rp rp-relative potency

European Union - English - EMA (European Medicines Agency)

intervet international bv - porcine circovirus type 2 orf2 subunit antigen - immunologicals for suidae - pigs - for the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce weight loss associated with porcine-circovirus-type-2 infection occurring during the fattening period.onset of immunity: 2 weeksduration of immunity: 22 weeks

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - porcine circovirus recombinant virus (cpcv) 1-2, inactivated - immunologicals - pigs (piglets) - active immunisation of pigs over the age of three weeks against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with pcv2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with post-weaning multisystemic wasting syndrome.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (pcv2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with pcv2-related disease (pcvd).in addition, vaccination has been shown to reduce pcv2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.